These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30767738)

  • 41. Shape Characterization of Subvisible Particles Using Dynamic Imaging Analysis.
    Mathaes R; Manning MC; Winter G; Engert J; Wilson GA
    J Pharm Sci; 2020 Jan; 109(1):375-379. PubMed ID: 31476311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance.
    Boll B; Bessa J; Folzer E; Ríos Quiroz A; Schmidt R; Bulau P; Finkler C; Mahler HC; Huwyler J; Iglesias A; Koulov AV
    Mol Pharm; 2017 Apr; 14(4):1292-1299. PubMed ID: 28206769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Variable Threshold Method for Determining the Boundaries of Imaged Subvisible Particles.
    Cavicchi RE; Collett C; Telikepalli S; Hu Z; Carrier M; Ripple DC
    J Pharm Sci; 2017 Jun; 106(6):1499-1507. PubMed ID: 28209364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Introducing the Alba
    Chillon A; Pace A; Zuccato D
    PDA J Pharm Sci Technol; 2018; 72(4):382-392. PubMed ID: 29853611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
    Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
    J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence.
    Maddux NR; Daniels AL; Randolph TW
    J Pharm Sci; 2017 May; 106(5):1239-1248. PubMed ID: 28159641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Approaches to reducing subvisible particle counts in lyophilized parenteral formulations.
    Gupta PK; Porembski E; Williams NA
    J Pharm Sci Technol; 1994; 48(1):30-7. PubMed ID: 8004415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Strengths of Total Holographic Video Microscopy in Detecting Sub-Visible Protein Particles in Biopharmaceuticals: A Comparison to Flow Imaging and Resonant Mass Measurement.
    Rahn H; Oeztuerk M; Hentze N; Junge F; Hollmann M
    J Pharm Sci; 2023 Apr; 112(4):985-990. PubMed ID: 36596393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Flow Imaging Analysis for Subvisible Particle Characterization in Glatiramer Acetate.
    Levin I; Zigman S; Komlosh A; Kettenring J
    J Pharm Sci; 2015 Nov; 104(11):3977-3983. PubMed ID: 26099719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of Temporal Aggregation Processes Using Spatial Intensity Distribution Analysis.
    Rattray Z; Zindy E; Buzza KM; Pluen A
    Methods Mol Biol; 2019; 2039():141-155. PubMed ID: 31342425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis.
    Strehl R; Rombach-Riegraf V; Diez M; Egodage K; Bluemel M; Jeschke M; Koulov AV
    Pharm Res; 2012 Feb; 29(2):594-602. PubMed ID: 21948455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An interlaboratory comparison of sizing and counting of subvisible particles mimicking protein aggregates.
    Ripple DC; Montgomery CB; Hu Z
    J Pharm Sci; 2015 Feb; 104(2):666-77. PubMed ID: 25421933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
    Nayak A; Colandene J; Bradford V; Perkins M
    J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.